17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and Colonic-Neoplasms

17-(dimethylaminoethylamino)-17-demethoxygeldanamycin has been researched along with Colonic-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and Colonic-Neoplasms

ArticleYear
Glucose-regulated protein 78 mediates the therapeutic efficacy of 17-DMAG in colon cancer cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:6

    Glucose-regulated protein 78 (GRP78) is expressed as part of the molecular response to endoplasmic reticulum (ER) stress and mediates protein folding within the cell. GRP78 is also an important biomarker of cancer progression and the therapeutic response of patients with different cancer types. However, the role of GRP78 in the cytotoxic effect of 17-DMAG in colon cancer cells remains unclear. GRP78 expression was knocked down by small interfering RNA (siRNA). The anticancer effects of 17-DMAG were assessed by an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, a flow cytometric cell-cycle analysis, and an Annexin V-propidium iodide (PI) apoptotic assay. We found that HT-29 cells expressed a lower level of GRP78 compared with DLD-1 cells. The MTT assay revealed that HT-29 cells were more sensitive to 17-DMAG treatment than DLD-1 cells. GRP78 knock down (GRP78KD) cells demonstrated an increased sensitivity to 17-DMAG treatment compared with the scrambled control cells. Based on the cell-cycle analysis and Annexin V-PI apoptotic assay, apoptosis dramatically increased in GRP78KD cells compared with scrambled control DLD-1 cells after these cells were treated with 17-DMAG. Finally, we observed a decrease in the level of Bcl-2 and an increase in the levels of Bad and Bax in GRP78KD cells treated with 17-DMAG. These results are consistent with an increased sensitivity to 17-DMAG after knock down of GRP78. The level of GRP78 expression may determine the therapeutic efficacy of 17-DMAG against colon cancer cells.

    Topics: Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Benzoquinones; Cell Cycle; Cell Proliferation; Colonic Neoplasms; Endoplasmic Reticulum Chaperone BiP; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; HT29 Cells; Humans; Lactams, Macrocyclic; Proto-Oncogene Proteins c-bcl-2

2015
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.
    BMC cancer, 2010, Dec-03, Volume: 10

    Activating transcription factor-3 (ATF3) is involved in the complex process of cellular stress response. However, its exact role in cancer is discussed controversially because both tumor suppressive and oncogenic effects have been described. Here we followed-up on our previous observation that inhibition of Hsp90 may increase ATF3 expression and sought to determine the role of ATF3 in colon cancer.. Regulation of ATF3 was determined in cancer cells using signaling inhibitors and a heat-shock protein-90 (Hsp90) antagonist. Human HCT116 cancer cells were stably transfected with an ATF3-shRNA or a luciferase-shRNA expression plasmid and alterations in cell motility were assessed in migration assays. The impact of ATF3 down-regulation on cancer growth and metastasis were investigated in a subcutaneous tumor model, a model of hepatic tumor growth and in a model of peritoneal carcinomatosis. Human colon cancer tissues were analyzed for ATF3 expression.. The results show that therapeutic Hsp90 inhibition substantially up-regulates the expression of ATF3 in various cancer cells, including colon, gastric and pancreatic cancer. This effect was evident both in vitro and in vivo. RNAi mediated knock-down of ATF3 in HCT116 colon cancer cells significantly increased cancer cell migration in vitro. Moreover, in xenogenic mouse models, ATF3 knock-down promoted subcutaneous tumor growth and hepatic metastasis, as well as peritoneal carcinomatosis. Importantly, ATF3 expression was lower in human colon cancer specimens, as compared to corresponding normal surrounding tissues, suggesting that ATF3 may represent a down-regulated tumor suppressor in colon cancer.. In conclusion, ATF3 down-regulation in colon cancer promotes tumor growth and metastasis. Considering that blocking Hsp90 induces ATF3 expression, Hsp90 inhibition may represent a valid strategy to treat metastatic colon cancer by up-regulating this anti-metastatic transcription factor.

    Topics: Activating Transcription Factor 3; Animals; Antineoplastic Agents; Benzoquinones; Cell Movement; Colonic Neoplasms; HCT116 Cells; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Liver Neoplasms; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Peritoneal Neoplasms; RNA Interference; Time Factors; Transfection; Tumor Burden; Up-Regulation

2010